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This randomized, double-blind study compared the efﬁcacy and safety of blonanserin and risperidone to
treat Chinese schizophrenia patients aged 18 and < 65 years. Patients with Positive and Negative
Syndrome Scale (PANSS) total scores 70 and  120 were randomized to receive blonanserin or ris-
peridone using a gradual dose-titration method (blonanserin tablets: 8e24 mg/day; risperidone tablets:
2e6 mg/day), twice daily. Treatment populations consisted of 128 blonanserin-treated patients and 133
risperidone-treated patients. Intention-to-treat analysis was performed using the last observation car-
ried forward method. Reductions of PANSS total scores by blonanserin and risperidone treatment
were 30.59 and 33.56, respectively. Risperidone treatment was associated with elevated levels of
serum prolactin (67.16% risperidone versus 52.31% blonanserin) and cardiac-related abnormalities
(22.39% risperidone versus 12.31% blonanserin), and blonanserin patients were more prone to extra-
pyramidal side effects (48.46% blonanserin versus 29.10% risperidone). In conclusion, blonanserin was as
effective as risperidone for the treatment of Chinese patients with schizophrenia. The overall safety
proﬁles of these drugs are comparable, although blonanserin was associated with a higher incidence of
EPS and risperidone was associated with a higher incidence of prolactin elevation and weight gain. Thus,
blonanserin is useful for the treatment of Chinese schizophrenia patients.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1@qq.com (C. Yao), sjgysh@
angqi0208@126.com (S. Qi),
(H. Zhang), biglijie@163.com
.com (C. Wang), liucui0723@
wangqiang130@hotmail.com
.com.cn (X. Luo), guniufan@
Ltd. This is an open access article u1. Introduction
Schizophrenia is a psychiatric disease with unknown etiology.
Unlike other neurodevelopmental disorders where disease occurs
early in life, schizophrenia is thought to have a latency period of up
to 30 years (Lieberman et al., 2001). A 1998 study in China reportednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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in urban areas compared with 5.18 per 1000 people in rural areas,
and the total incidence of schizophrenia was 5.31 per 1000 people
(Zhang et al., 1998).
Antipsychotic drugs are currently recommended as a ﬁrst-line
clinical therapy (Chinese Medical Association, 2007) for the treat-
ment of schizophrenia in China and other countries (National
Institute for Health and Care Excellence, 2009). Typical antipsy-
chotics block dopamine D2 receptors and provide effective treat-
ment of positive symptoms such as hallucinations and delusions,
but have a limited efﬁcacy on negative symptoms such as reduced
emotional expression (blunted affect) and social withdrawal.
Furthermore, typical antipsychotics can induce a number of
potentially severe side effects (extrapyramidal side effects [EPS],
tardive dyskinesia, malignant syndrome, and hyperprolactinemia)
that may limit their use in many patients (Chue and Lalonde, 2014).
In contrast to typical antipsychotics, atypical antipsychotics have a
high afﬁnity for 5-HT2A and D2 receptors. Importantly, they are
effective against both positive and negative symptoms, reduce the
frequency of EPS, and have fewer side effects than typical anti-
psychotics (Rosenzweig-Lipson et al., 2012). However, some atyp-
ical antipsychotics are associated with a high risk of metabolic
abnormalities, including weight gain and abnormal glucose toler-
ance. Therefore, use of atypical antipsychotics does not fully resolve
all issues regarding the safety proﬁle of antipsychotics (Stahl, 2010).
Blonanserin is a new atypical antipsychotic that selectively
blocks 5-HT2 and D2 receptors, and is now available for the treat-
ment of schizophrenic patients in Japan and Korea (Une and
Kurumiya, 2007). Three randomized double-blind studies in Japan
and Korea to evaluate its efﬁcacy and tolerability demonstrated that
blonanserin has a greater beneﬁcial effect on the negative symp-
toms of schizophrenia patients than does haloperidol, and that
there was a signiﬁcant difference in the adverse event proﬁle be-
tween blonanserin, haloperidol and risperidone (Murasaki, 2007;
Miura, 2008; Yang et al., 2010).
The objective of this randomized, double-blind, parallel-
controlled, multicenter study was to compare the efﬁcacy and
safety of blonanserin for the treatment of schizophrenia using ris-
peridone as a control drug.
2. Subjects and methods
2.1. Study design and patients
This was a randomized, double-blind, and parallel-controlled
multicenter clinical trial. The registration period was between
February 2nd, 2012 (the date of obtaining informed consent date
from the ﬁrst subject) and February 19th, 2013. The study enrolled
267 subjects including 131 in the trial group and 136 in the control
group from 13 institutes (Supplementary Table 1). The study was
carried out in accordance with Good Clinical Practice issued by the
China Food and Drug Administration (2003) and the latest version
of the Declaration of Helsinki. The patient or legal guardians signed
the informed consent form after the nature of the procedures had
been fully explained. This study was registered with Clinical-
Trials.gov, number NCT01516424.
Inclusion criteria included schizophrenic patients meeting the
Diagnostic and Statistical Manual of Mental DisorderseIVetext
revision (DSMeIVeTR) Diagnostic Criteria for Schizophrenia. Full
details of inclusion and exclusion criteria are shown in
Supplementary Table 2.
Subjects were assigned to either the study or control group at a
ratio of 1:1 by a dynamic randomization method. Eligible patients
were randomized via an Interactive Web Response System and
were administered the study drug according to randomizationresults. The screening period started from the date of signing the
informed consent form. Eligible patients completed randomization
within 14 days after screening and the baseline was set (screening
period 14 days with a washout period within the screening
period, 24 h and <7 days). The treatment period included follow-
up visits on days 7, 14, 28, 42, and 56 with a window of ±2 days.
Subjects then entered the dose reduction and observation period
between days 57 and 70.2.2. Treatments
This trial employed a gradual dose-titration dosing in the ﬁrst 2
weeks, which became ﬂexible up to 56 days (blonanserin tablets:
8e24 mg/day; risperidone tablets: 2e6 mg/day). Subjects received
doses twice daily after breakfast and dinner. The interval between
two dose adjustments was not shorter than 3 days. The concomi-
tant use of antipsychotics, antidepressants, anxiolytics (including
benzodiazepines, mood stabilizers, prophylactic use of anticholin-
ergics and electroconvulsive therapy) was prohibited from the
washout period to the end of treatment. Medications used for
movement disorders were tapered and discontinued before
randomization, but diphenhydramine (up to 50 mg/day), trihex-
yphenidyl (up to 10 mg/day) and promethazine (up to 200 mg/day)
could be used if symptoms emerged. Lorazepam (up to 3 mg/day)
was permitted to treat clinically signiﬁcant agitation symptoms.
Hypnotics, zolpidem (up to 10 mg/day), zopiclone (up to 7.5 mg/
day), and zaleplon (up to 3 mg/day) could be given for the treat-
ment of insomnia. Lorazepam and hypnotics were not administered
within 12 h before assessment with Positive and Negative Syn-
drome Scale (PANSS), Clinical Global ImpressioneSeverity (CGI-S),
CGIeImprovement (CGI-I), SimpsoneAngus Scale (SAS), and the
Barnes Akathisia Rating Scale (BARS).2.3. Efﬁcacy endpoints
The primary efﬁcacy end point was the mean change in PANSS
total score from baseline to the end of treatment (day 1 as baseline).
Secondary efﬁcacy measures were changes in PANSS subscale total
scores, PANSS ﬁve-factor model total scores, and PANSS symptom
scores to the end of treatment, PANSS symptom scores at each
evaluation period, changes in CGI-S scores at the end of treatment
and CGI-I scores at each evaluation period (Lindenmayer et al.,
1994). The PANSS is a 30-item, 7-point rating system with a score
for each item in the range 1e7, and a total score in the range
30e210. CGI-I and CGI-S are 7-point rating scales. Higher scores on
these scales represent increasing levels of psychopathology.2.4. Safety
Treatment-emergent adverse events (TEAEs) and drug-related
TEAEs were deﬁned as adverse events occurring during treatment
and dose-decreasing observation periods with an occurrence no
earlier than ﬁrst-time medication, or which occurred before ﬁrst-
time medication but were exacerbated during treatment or the
dose-decreasing observation period. TEAEs were coded using
MedDRA version 15.1 (Chinese/English) by system organ class and
preferred term. Extrapyramidal TEAEs, prolactin-related TEAEs, and
cardiac TEAEs were listed as special interest TEAEs. The SAS, a 10-
item rating scale, was used to evaluate antipsychotic-induced Par-
kinson symptoms and severity (Simpson and Angus, 1970) and
BARS, a 4-item rating scale, was used to evaluate drug-induced
akathisia and severity (Barnes, 1989).
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The primary objective was to show non-inferiority of blo-
nanserin to risperidone as the primary variable of change from
baseline in PANSS total score at the end of study treatment in the
intention-to-treat (ITT) population. This population included pa-
tients who were randomized, took at least one dose of study
medication, and had baseline and at least one post-baseline PANSS
evaluation. The per-protocol population included patients from the
ITT population without major protocol deviation. The safety pop-
ulation included all randomized patients who took at least one dose
of study medication, and they were used for safety analyses.
The sample size of 97 patients for each treatment group was
calculated as giving 80% power with 2.5% of one-sided alpha, stan-
dard deviation of 17.4, mean treatment difference of zero, and non-
inferiority margin of 7.0. The non-inferiority margin was deter-
mined before initiation of the study based on previous risperidone-
controlled non-inferiority studies (Marder and Meibach, 1994;
Perkins et al., 2000; Kamijima et al., 2009; Yang et al., 2010).
The primary analysis was performed using an analysis of
covariance (ANCOVA) model including treatment and pooled study
center as factor and baseline value as covariates, where missing
values were imputed by the last observation carried forward (LOCF)
method. LOCFeANCOVA analysis was repeated to determine the
primary efﬁcacy variable using the per-protocol (PP) population.
The secondary analysis used a mixed-effect model for repeated
measures (MMRM) model including baseline value, treatment,
visit, and treatment-by-visit interaction with unstructured covari-
ate matrix for within subject correlation, and missing values were
not imputed. All statistics were computed using statistical analysis
software (Windows-based SAS 9.2). All statistical tests employed
two-sided tests. When values of Pwere0.05, the tested difference
was considered to have statistical signiﬁcance (unless noted
otherwise).3. Results
3.1. Subject characteristics
Of 318 subjects screened, 267 subjects were enrolled and
randomly assigned to treatment groups, of which 264 receivedFig. 1. Subject dtreatment (129 blonanserin, 135 risperidone), and 3 did not receive
study drugs. Fifty-one subjects failed screening. Among the study
subjects receiving a study drug, 210 (96 taking blonanserin and 114
taking risperidone) completed the study and 54 discontinued
treatment. The discontinuation rate was 35/131 (26.72%) for blo-
nanserin and 22/136 (16.18%) for risperidone among the random-
ized subjects (P ¼ 0.0291, Chi-square distribution). The main
reasons for discontinuation were: informed consent withdrawal
from subjects including subjects who were no longer willing to
continue hospitalization owing to improved conditions (n ¼ 13 for
blonanserin and n ¼ 8 for risperidone), adverse events (n ¼ 4 for
blonanserin and n ¼ 5 for risperidone), study protocol violation
(n¼ 5 for blonanserin and n¼ 3 for risperidone) and lack of efﬁcacy
(n ¼ 6 for blonanserin and n ¼ 1 for risperidone) (Fig. 1). Subject
characteristics are summarized in Table 1. The mean ages were
33.62 years (blonanserin) and 35.02 years (risperidone), and the
most prominent schizophrenia subtype was paranoid (60.16% and
57.14% for blonanserin and risperidone, respectively). All subject
characteristics were comparable between the treatment groups.
3.2. PANSS total scores
3.2.1. ITT analysis of PANSS total scores using LOCF
PANSS total scores at baseline were 93.46 (blonanserin) and
92.30 (risperidone), and the difference between groups was not
statistically signiﬁcant (P¼ 0.4392). PANSS total scores at the end of
treatment were 62.88 (blonanserin) and 58.74 (risperidone)
(Table 2). Mean changes from baseline were 30.59 (blonanserin)
and33.56 (risperidone) (both P < 0.0001). The least squaresmean
difference between the two groups was 3.69 (two-sided 95% con-
ﬁdence interval [CI]: 0.36, 7.75). The upper limit of the 95% CI was
over the non-inferiority margin of 7.0 in the primary efﬁcacy
analysis.
3.2.2. ITT analysis of PANSS total scores using MMRM
The mean changes of PANSS total scores from baseline to 8
weeks of treatment (ITT set) were34.70 (blonanserin) and36.97
(risperidone) (Table 3). The least squares mean difference between
the two groups was 2.28 (two-sided 95% CI: 1.29, 5.85). Because
the upper limit was less than 7.0, non-inferiority was demonstrated
in the additional analysis.istribution.
Table 1
Subject characteristics.
Item Indicator/type Blonanserin group
(N ¼ 128)
Risperidone group
(N ¼ 133)
Statistics P value
Age (years) Mean (SD) 33.62 (11.02) 35.02 (10.80) 1.04 (t value) 0.3016
Gender Male 58 (45.31%) 75 (56.39%) 3.20 (chi-square) 0.0735
Female 70 (54.69%) 58 (43.61%)
Hospital status Inpatient 118 (92.19%) 116 (87.22%) 1.74 (chi-square) 0.1875
Outpatient 10 (7.81%) 17 (12.78%)
Height (cm) Mean (SD) 165.80 (8.46) 166.01 (7.19) 0.21 (t value) 0.8315
Body weight (kg) Mean (SD) 61.75 (11.92) 62.66 (12.47) 0.61 (t value) 0.5442
Body mass index (kg/m2) Mean (SD) 22.43 (3.86) 22.71 (4.08) 0.56 (t value) 0.5790
Duration of illness (months) Mean (SD)
Min, Max
2.90 (13.61)
0, 107.42
2.32 (12.03)
0, 94.97
0.12 (rank sum) 0.9052
Subtype Paranoid
Disorganized
Catatonic
Undifferentiated
Residual
77 (60.16%)
2 (1.56%)
0 (0.00%)
49 (38.28%)
0 (0.00%)
76 (57.14%)
2 (1.50%)
0 (0.00%)
54 (40.60%)
1 (0.75%)
(Bilateral exact) 0.9057
Time between obtaining informed consent
and ﬁrst onset of disease (day)
Mean (SD)
Min, Max
2902.9 (2716.8)
193, 14,774
3034.4 (2727.4)
97, 13,942
0.47 (rank sum) 0.6407
Time between obtaining informed consent
and the onset of disease (day)
Mean (SD)
Min, Max
555.56 (1284.6)
1, 10,063
612.68 (1396.7)
2, 8096
0.73 (rank sum) 0.4674
Number of ﬁrst episodes Number (%) 35 (28.69%) 36 (28.35%) 0.00 (chi-square) 0.9523
Onset frequency (times) Mean (SD)
Min, Max
2.79 (2.12)
1, 11
2.87 (2.02)
1, 13
0.77 (rank sum) 0.4385
Antipsychotic treatment history None
Typical antipsychotic treatment
Atypical Antipsychotic Treatment
Both
28 (21.88%)
4 (3.13%)
58 (45.31%)
38 (29.69%)
24 (18.05%)
6 (4.51%)
54 (40.60%)
49 (36.84%)
(Bilateral exact) 0.5415
SD, standard deviation.
Table 2
Comparison of mean changes in PANSS total scores.
Group Item Blonanserin group (N ¼ 128)
mean (SD)
Risperidone group (N ¼ 133)
mean (SD)
ITT Baseline 93.46 (11.95) 92.30 (12.23)
End of treatment 62.88 (19.60) 58.74 (17.11)
End of treatment e Baseline 30.59 (18.53) 33.56 (16.89)
% change 48.62 (28.70) 54.11 (27.05)
PPS Baseline 93.86 (11.91) 92.80 (12.30)
End of treatment 60.15 (18.50) 56.49 (15.04)
End of treatment e Baseline 33.71 (17.02) 36.31 (14.09)
% change 53.51 (26.12) 58.53 (21.69)
Subjects that discontinued within 2 weeks
were removed
Baseline 93.99 (11.88) 92.48 (12.21)
End of treatment 60.98 (18.74) 57.02 (15.26)
End of treatment e Baseline 33.01 (17.10) 35.47 (14.63)
% change 52.33 (26.35) 57.33 (22.48)
ITT, intention-to-treat analysis set; PPS, per-protocol set; SD, standard deviation.
Positive and Negative Syndrome Scale (PANSS) subscale sores and ﬁve-factor model scores were also analyzed by the last observation carried forward-analysis of covariance
(LOCF-ANCOVA) model using the ITT population to compare blonanserin and risperidone.
Table 3
Comparison of mean changes of PANSS total scores from baseline to 8 weeks of treatment.
Groups LOCF-ANCOVA MMRM
ITT Blonanserin (N ¼ 128) 29.83 (32.85, 26.81) 34.70 (37.32, 32.07)
Risperidone (N ¼ 133) 33.53 (36.46, 30.59) 36.97 (39.46, 34.48)
Difference 3.69 (0.36, 7.75) 2.28 (1.29, 5.85)
PPS Blonanserin (N ¼ 113) 32.82 (35.57, 30.07) 34.84 (37.47, 32.20)
Risperidone (N ¼ 121) 35.76 (38.40, 33.12) 37.09 (39.59, 34.60)
Difference 2.94 (0.76,6.65) 2.25 (1.33, 5.84)
ITT, intention-to-treat analysis set; PPS, per-protocol set.
Data express least-square means (95% two-sided conﬁdence interval).
Mean changes of Positive and Negative Syndrome Scale (PANSS) total scores were analyzed by last observation carried forward-analysis of covariance model (LOCF-ANCOVA)
method assuming discontinued subjects are generated at random in both groups and mixed-effect model repeated measure (MMRM) method that is not susceptible to
discontinued subjects.
H. Li et al. / Journal of Psychiatric Research 69 (2015) 102e109 105
Fig. 4. General psychopathology scores decreased signiﬁcantly from baseline to the
end of treatment in the ITT population in both groups. The standard deviation (SD) at
each point is shown in parentheses. BNS, blonanserin; RIS, risperidone.
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The mean changes from baseline were 33.71 (blonanserin)
versus 36.31 (risperidone) (both P < 0.0001, Table 2). The least
squares mean difference was 2.94 (two-sided 95% CI: 0.76, 6.65).
Because the upper limit of 6.65 was less than 7.0, non-inferiority
was demonstrated in the additional analysis.
3.2.4. Analysis of primary efﬁcacy measures after removing early
discontinued (<2 weeks) subjects
The onset of antipsychotic medication efﬁcacy requires more
than 2 weeks. Therefore, to compare efﬁcacy between the two
groups, subjects taking drugs for less than 2 weeks were excluded
from the ITT set for analysis (Table 2). Mean changes in PANSS total
scores from baseline were 33.01 (blonanserin) and 35.47 (ris-
peridone). The least squares mean difference was 3.04 (two-sided
95% CI:0.70, 6.79). Because the upper limit was less than 7.0, non-
inferiority was demonstrated in the additional analysis.
3.3. PANSS subscale scores
The PANSS subscale (positive, negative and general psychopa-
thology) scores decreased signiﬁcantly from baseline to the end of
treatment in both groups (both P < 0.05; paired t-test), as shown in
Figs. 2e4.
The PANSS 5-factor model (negative symptoms, excitation,
cognitive disorders, positive symptoms, anxiety/depression) scoresFig. 2. Positive subscale scores decreased signiﬁcantly from baseline to the end of
treatment in the ITT population in both groups. The standard deviation (SD) at each
point is shown in parentheses. BNS, blonanserin; RIS, risperidone.
Fig. 3. Negative subscale scores decreased signiﬁcantly from baseline to the end of
treatment in the ITT population in both groups. The standard deviation (SD) at each
point is shown in parentheses. BNS, blonanserin; RIS, risperidone.decreased signiﬁcantly from baseline to the end of treatment in
both groups (both P < 0.05), as shown in Fig. 5.
3.4. On-treatment changes in PANSS scores
During the treatment period, the PANSS total scores, subscale
scores, 5-factor model scores, and symptom scores were signiﬁ-
cantly lower in both groups after 1 week of treatment than at
baseline (both P < 0.05), and continued to decrease thereafter
(weeks 2, 4, 6, and 8 after initiation of drug treatment). There were
no signiﬁcant differences (P > 0.05) in terms of the mean changes
from baseline to each visit between the two groups.
3.5. CGI-S scores from baseline to each visit (ITT set)
The mean changes in CGI-S scores from baseline were 1.59
(blonanserin) versus 1.78 (risperidone) (Table 4). The signed rank
sum test showed that the changes in CGI-S were signiﬁcant within
both groups (P < 0.0001), but the mean changes between the
groups were not signiﬁcant (P ¼ 0.1536). The rate of subjects with
3 scores of CGI-S changed from 0.78% to 65.63% in the blonanserin
group from baseline to week 8 treatment compared with a change
from 0% to 64.91% in the risperidone group.
3.6. Treatment-emergent adverse events
Safety analyses were performed in 264 subjects (n ¼ 130 blo-
nanserin group, n ¼ 134 risperidone group). During the study, 126Fig. 5. The PANSS 5-factor model scores decreased signiﬁcantly from baseline to the
end of treatment in the ITT population in both groups.
Table 4
Comparison of mean changes in CGI-S from baseline to each visit (ITT set).
Item Blonanserin
group
(N ¼ 128)
Risperidone
group
(N ¼ 133)
Test
statistic
P
value
Baseline 0.11
(rank sum)
0.9128
N (Missing) 128 (0) 133 (0)
Mean (SD) 5.11 (0.62) 5.14 (0.63)
Min, Max 3, 6 4, 7
Md (Q3eQ1) 5.00 (0.00) 5.00 (0.00)
Q1, Q3 5.00, 5.00 5.00, 5.00
End of treatment 1.06
(rank sum)
0.2891
N (Missing) 128 (0) 132 (1)
Mean (SD) 3.52 (1.19) 3.36 (1.12)
Min, Max 1, 6 1, 7
Md (Q3eQ1) 3.00 (1.00) 3.00 (1.00)
Q1, Q3 3.00, 4.00 3.00, 4.00
End of treatment e
Baseline
1.43
(rank sum)
0.1536
N (Missing) 128 (0) 132 (1)
Mean (SD) 1.59 (1.15) 1.78 (1.10)
Min, Max 4, 1 5, 1
Md (Q3eQ1) 2.00 (1.00) 2.00 (1.00)
Q1, Q3 2.00, 1.00 2.00, 1.00
Signed rank
sum (P value)
2848
(<.0001)
3589
(<.0001)
Md (Q3eQ1), median (interquartile range); SD, standard deviation; CGI-S, Clinical
Global ImpressioneSeverity.
CGI-Improvement scores and changes from baseline were analyzed using Wilcox-
on's signed rank-sum test.
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subjects in the risperidone group (91.04%; 506 events) reported
TEAEs. Moreover, study drug-related TEAEs were reported by 113
subjects in the blonanserin group (86.92%; 299 events) and 115
subjects in the risperidone group (85.82%; 341 events). The ma-
jority of TEAEs were mild or moderate.
The most common study drug-related TEAEs (10%) in the
blonanserin and risperidone groups were increased serum prolac-
tin (52.31% and 67.16%, respectively), EPS (48.46% and 29.10%,
respectively), constipation (16.15% and 16.42%, respectively), and
liver function abnormalities (6.92% and 12.69%, respectively)
(Table 5). Importantly, no deaths resulting from TEAEs were re-
ported in either group. Six subjects in the blonanserin group
(4.62%) and four in the risperidone group (2.99%) discontinued
treatment because of adverse events. Severe AEs occurred in one
subject in the blonanserin group (0.77%; chickenpox, not related),
and in three subjects in the risperidone group (2.24%; urinaryTable 5
Treatment-emergent adverse events occurring in 2% of patients in either group (safety
SOC PT Blonanserin group (N ¼ 130)
Number of subjects Number of cases Incid
Gastrointestinal system disorders
Constipation 21 28 16.15
Hepatobiliary system diseases
Abnormal liver function 9 9 6.92
Infections and infectious diseases
Nasopharyngitis 14 16 10.77
Examinations
Serum prolactin increase 68 68 52.31
Neurological disorders
Extrapyramidal disorders 63 71 48.46
Psychiatric disorders
Excitement 28 32 21.54
Insomnia 24 31 18.46
SOC, System Organ Class; PT, Preferred Terms.retention, possibly related; gastrointestinal foreignmatter, possibly
not related; and fever, possibly related).
3.6.1. Extrapyramidal TEAEs
Extrapyramidal TEAEs in this study are EPS including extrapy-
ramidal disease, akathisia, tremor, skeletal muscle rigidity, difﬁ-
culty in swallowing, and torticollis. During the study,
extrapyramidal TEAEs occurred in 56.15% of subjects in the blo-
nanserin group and in 32.84% of those in the risperidone group. The
most common extrapyramidal TEAE was extrapyramidal disease,
which occurred in 48.46% of subjects in the blonanserin group and
in 29.10% in the risperidone group. Most subjects experienced mild
extrapyramidal disease, but one subject in the risperidone group
experienced severe extrapyramidal disease. The incidence of EPS
was dose-dependent in both groups.
The SAS total scores change were not statistically signiﬁcant
between the two groups (P¼ 0.5408). The BARS total scores change
were signiﬁcantly different in the blonanserin group compared
with the risperidone group (P ¼ 0.0474).
3.6.2. Body weight and vital signs
The paired t-test analysis of within-group changes in body
weight from baseline to 4 weeks after drug treatment showed a
non-signiﬁcant change in the blonanserin group (0.46 kg; P > 0.05),
compared with a signiﬁcant change in the risperidone group
(1.25 kg; P < 0.0001). An increase in body weight of 7% at the end
of treatment was seen in 13.82% of subjects in the blonanserin
group and 21.71% of subjects in the risperidone group.
The vital signs (systolic blood pressure, diastolic blood pressure,
heart rate, and body temperature) of both groups from baseline to
the end of treatment did not change signiﬁcantly, and comparisons
between the two groups were not statistically signiﬁcant (P > 0.05).
3.6.3. Prolactin-related side effects
An additional analysis after unblinding indicated that the inci-
dence of prolactin-related TEAEwas lower in the blonanserin group
than in the risperidone group (52.31% versus 68.66%, respectively),
but a causal relationship to the study drug could not be ruled out in
most cases. The only prolactin-related TEAEs in the blonanserin
group were increased blood prolactin levels, whereas increased
blood prolactin levels, galactorrhea and hyperprolactinemia were
observed in the risperidone group. The increase in prolactin levels
in both groups was considered mild: blood prolactin levels were
similar in the blonanserin and risperidone groups at baseline (40.75
versus 32.21 ng/mL, respectively; P ¼ 0.0872). Prolactin levels
increased at week 4e66.31 and 85.12 ng/mL in the blonanserin and
risperidone groups, respectively (mean change from baseline:analysis set).
Risperidone group (N ¼ 134)
ence rate (%) Number of subjects Number of cases Incidence rate (%)
22 34 16.42
17 17 12.69
20 23 14.93
90 90 67.16
39 41 29.10
16 19 11.94
18 25 13.43
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respectively, at the end of treatment (mean change from baseline:
12.24 and 62.17 ng/mL, respectively). The increases in prolactin
levels were statistically signiﬁcant in both groups, and were
signiﬁcantly greater in the risperidone group than in the blo-
nanserin group.
Similar proportions of subjects in both groups had unfavorable
changes in routine blood, biochemical, and urinalysis tests after 4
and 8weeks of treatment. Themost common event was an increase
in blood prolactin.
3.6.4. Cardiac-related TEAEs
The incidence of cardiac-related TEAEs was lower in the blo-
nanserin group than in the risperidone group (12.31% versus
22.39%), but a causal relationship to the study drug could not be
ruled out in most cases. In both groups, the majority of cardiac-
related TEAEs were mild, and the most common TEAE was palpi-
tations in the blonanserin and risperidone groups (6.15% and 9.70%,
respectively). Clinically relevant 12-lead ECG abnormalities were
detected in more subjects from the risperidone group after 4 and 8
weeks of treatment (risperidone versus blonanserin: nine versus
ﬁve cases, respectively, at Week 4, and four versus two cases,
respectively, at Week 8). The clinically relevant 12-lead ECG ab-
normalities were abnormalities in ECG (n ¼ 1) in 1 subject treated
with blonanserin, and shortened PR (n ¼ 2), prolonged QT (n ¼ 1),
and abnormalities in ECG (n ¼ 1) in 4 subjects treated with
risperidone.
4. Discussion
This randomized, double-blind, parallel-controlled, multicenter
study compared the efﬁcacy and safety of blonanserin using ris-
peridone as a control drug for the treatment of schizophrenia. All
efﬁcacy indicators were analyzed using both the ITT (primary
analysis set) and the PP sets (secondary analysis set). The results of
the primary objective demonstrated that although non-inferiority
was not veriﬁed in the ITT set, the efﬁcacy of blonanserin was
non-inferior to risperidone based on results from the PP set. Thus,
the PP set appears to be more suitable than the ITT set for
comparing differences between study drugs by the non-inferiority
test. Moreover, according to ICH guideline E9, in the non-inferiority
trial, the use of the full analysis set is generally not conservative and
its role should be considered very carefully. Possible reasons why
ITT analysis did not verify non-inferiority are that ITT analysis
included subjects who took drugs for less than 2 weeks, and use of
the LOCF method causing efﬁcacy data to be conservative. When
subjects that discontinued treatment within 2 weeks were
removed from the ITT set, analysis indicated non-inferiority of
blonanserin because it is generally known that antipsychotics
require at least 2e3 weeks to be efﬁcacious. Therefore, blonanserin
is effective for schizophrenia.
The MMRM method is widely used in clinical studies and is an
alternative to LOCF. The LOCF method premised that discontinued
subjects were generated at random in both groups. However, in this
study, the number of discontinued subjects in the blonanserin
group was greater than in the risperidone group. The MMRM
method is not susceptible to discontinued subjects and additional
analysis by MMRM veriﬁed the non-inferiority of blonanserin in
both the PP and ITT sets.
A previous study comparing blonanserin with haloperidol in
acute-phase schizophrenia patients showed that blonanserin had a
better efﬁcacy and improved both positive and negative symptoms,
whereas haloperidol improved only positive symptoms (Garcia
et al., 2009). Moreover, a Korean study demonstrated blonanserin
was effective for the treatment of schizophrenic patients and wasnon-inferior to risperidone (Yang et al., 2010). In addition, blo-
nanserin had a better safety proﬁle than haloperidol with regard to
prolactin elevation and EPS frequency (Garcia et al., 2009) and a
better safety proﬁle than risperidone with regard to prolactin
elevation (Yang et al., 2010). A systematic review and meta-analysis
of randomized, controlled trials comparing blonanserin with other
antipsychotics validated the safety and efﬁcacy of blonanserin for
schizophrenia treatment and showed it had greater efﬁcacy for the
treatment of negative symptoms compared with haloperidol;
blonanserin-treated patients also had a lower risk of hyper-
prolactinemia than those treated with haloperidol or risperidone
(Kishi et al., 2013).
A meta-analysis of the results of the current study and
risperidone-controlled phase III clinical studies of blonanserin
implemented in Japan and South Korea (Yang et al., 2010; Miura,
2008) was conducted. Of 775 schizophrenia patients analyzed,
the least square means (95% CI) of mean changes of PANSS total
scores were: 1.67 (0.90, 4.24), positive ¼ 0.59 (0.30, 1.48),
negative ¼ 0.06 (0.66, 0.79), and general psychopathology ¼ 1.01
(0.29, 2.32). Therefore, scores from baseline to the end of
treatment for blonanserin and risperidone groups were not
signiﬁcantly different (P ¼ 0.20, 0.19, 0.87, and 0.13, respectively).
All secondary efﬁcacy measures were signiﬁcantly improved at
the end of the treatment comparedwith the baseline (P < 0.01). The
positive symptom score and anxiety/depression score in the PANSS
5-factors in the risperidone group decreasedmore than those in the
blonanserin group (P ¼ 0.0265 and P ¼ 0.005, respectively). How-
ever, there were no signiﬁcant differences in the other PANSS 5-
factor model and CGI-S scores. Therefore, blonanserin can be
considered to be an effective agent for schizophrenia treatment
with a similar efﬁcacy to risperidone.
The incidences of TEAEs and drug-related TEAEswere similar for
both drug groups. EPS are common during antipsychotic therapy.
Although the blonanserin group had a higher incidence of EPS
(most were mild and only one case discontinued treatment), the
incidences of other TEAEs were the same or lower (heart disease-
related TEAEs, weight gain, increased serum prolactin, and
elevated hepatic enzymes) when compared with risperidone.
Because EPS are dose-dependent, decreasing the dose correctly
could reduce EPS; furthermore, treatment with an anti-Parkinson
drug might also be considered. Thus, EPS are not an obstacle to
continual blonanserin treatment.
Increased serum prolactin levels and related TEAEs were
observed in both groups and are relatively common during anti-
psychotic drug treatment. Increased serum prolactin levels can
cause menstrual abnormalities and infertility in women and low
libido in men. In other studies (Kamijima et al., 2009; Miura, 2008),
the mean changes of increased serum prolactin level were also
greater in the risperidone group than in the blonanserin group. It is
suggested that the relatively lower risk of serum prolactin increase
is caused by a good bloodebrain barrier permeability of blo-
nanserin (Tateno et al., 2013).
The incidence of weight gain in the blonanserin groups was
lower than in the risperidone groups. One case of prolonged QTwas
observed in the risperidone group and none in the blonanserin
group. Therefore, the lower incidence of serum prolactin increase,
cardiac-related abnormal changes and the low incidence of weight
gain by blonanserin are advantageous.
In the current study, the discontinuation rate was higher for
blonanserin than for risperidone. However, meta-analysis of indi-
vidual patient data from randomized controlled trials comparing
blonanserinwith other antipsychotics showed no differences in the
discontinuation rate due to any cause, inefﬁcacy, adverse events, or
death between blonanserin and other pooled antipsychotics (Kishi
et al., 2013).
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to consider for the treatment of schizophrenia.
Although blonanserin and risperidone act as antagonists at
dopamine D2 and serotonin 5-HT2A receptors, blonanserin has a
different effect from risperidone in the management of schizo-
phrenia based on its distinctive pharmacology and safety proﬁle.
Blonanserin has a higher binding afﬁnity for D2 receptors than for
5-HT2A receptors and acts as a D2 antagonist, whereas risperidone
has a higher binding afﬁnity for 5-HT2A receptors than for D2 re-
ceptors, as well as a high binding afﬁnity for the adrenergic a1
receptor (Murasaki et al., 2008). Given this high afﬁnity for the D2
receptor, blonanserin is recommended for schizophrenia patients
with symptoms mediated by dopamine receptors, such as signiﬁ-
cant positive symptoms or delusion/hallucination. Conversely, ris-
peridone may be a better choice in patients with psychomotor
excitement owing to its better sedation effect resulting from
adrenergic a1 receptor binding. However, oversedationmay cause a
deterioration of negative symptoms and negative symptoms
induced by the antipsychotics. In the present study, there was no
difference in the efﬁcacy of blonanserin and risperidone in treating
positive symptoms and negative symptoms in acute-phase
schizophrenia patients. Therefore, it is essential to choose medi-
cines based on clinical circumstances and adjust the dosage ac-
cording to each patient's response.
Additionally, in terms of safety, although the blonanserin group
had a higher incidence of EPS than the risperidone group in the
present study, the severity of EPS was similar for both agents. Meta-
analyses (Kishi et al., 2013, 2014) have found no signiﬁcant differ-
ence in the frequency of EPS between blonanserin and risperidone,
and that blonanserin had a lower risk of hyperprolactinemia and
weight gain than risperidone.
Therefore, treatment with blonanserin might be more suitable
for the following patients: those who need to be monitored care-
fully for metabolic system disorders; young patients with concerns
about menstrual disorders or sexual dysfunction caused by pro-
lactin level increases; and those with circulation system disorders
(adrenergic a1 antagonism by risperidone is associated with a
relatively high risk of cardiovascular events).
A study limitation was the relatively limited number of study
subjects. Future, large-scale clinical studies of blonanserin for
Chinese patients will be help for the decision-making of psychia-
trists when prescribing drugs to treat schizophrenic patients.
5. Conclusions
Blonanserin was as effective as risperidone for the treatment of
Chinese patients with schizophrenia, as determined by the total
PANSS scores. The overall safety proﬁles of these drugs are com-
parable, although blonanserin demonstrated a higher incidence of
EPS and risperidone demonstrated a higher incidence of prolactin
elevation and weight gain. Thus, blonanserin is a useful and novel
treatment option for Chinese patients with schizophrenia.
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